A startup developing new cancer treatments recently signed its second tech transfer deal with the University of Maryland, Baltimore.
Three-year-old Educational & Scientific, LLC (ESL) licensed technology designed to inhibit growth of prostate cancer with a specific form of the disease, according to UM Ventures. The molecule was developed as a therapeutic agent by University of Maryland School of Medicine professors Vincent C.O. Njar and Angela Brodie.
E. Albert Reece, dean of the University of Maryland School of Medicine Dean, said the collaboration is “a great example of how we can combine basic science with new potential therapies to treat cancer.”
READ FULL ARTICLE HERE
